676134-13-7Relevant articles and documents
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Prime side chromane-containing inhibitors
Ng, Raymond A.,Sun, Minghua,Bowers, Simeon,Hom, Roy K.,Probst, Gary D.,John, Varghese,Fang, Lawrence Y.,Maillard, Michel,Gailunas, Andrea,Brogley, Louis,Neitz, R. Jeffrey,Tung, Jay S.,Pleiss, Michael A.,Konradi, Andrei W.,Sham, Hing L.,Dappen, Michael S.,Adler, Marc,Yao, Nanhua,Zmolek, Wes,Nakamura, David,Quinn, Kevin P.,Sauer, John-Michael,Bova, Michael P.,Ruslim, Lany,Artis, Dean R.,Yednock, Ted A.
, p. 4674 - 4679 (2013/08/23)
The structure activity relationship of the prime region of conformationally restricted hydroxyethylamine (HEA) BACE inhibitors is described. Variation of the P1′ region provided selectivity over Cat-D with a series of 2,2-dioxo-isothiochromanes and optimi
METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS
-
Page/Page column 230-231, (2010/02/14)
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.